Risk of transplantrelated mortality doesn’t increase with cord blood

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

This study shows that in patients with acute leukemia, cord blood can be a good alternative,” said Dr. Keating, director of the division of hematology at the University of Toronto.

This study shows that in patients with acute leukemia, cord blood can be a good alternative,” said Dr. Keating, director of the division of hematology at the University of Toronto.

“For stem cell transplants, often there is some urgency, and finding a suitable peripheral blood or bone marrow donor can take a while. The advantage of cord blood is that these cells are typed and cryopreserved, so access to them could be faster.”

In a patient with acute myeloid leukemia in second remission, where time may be important, “it would be appropriate to do a cord blood transplant,” added Dr. Keating, who is also a professor of medicine at the University of Toronto.

Among some physicians, he said, “there may be a perception that using cord blood for stem cell transplants is riskier than peripheral blood or bone marrow sources. Certainly, the immunologic recovery is slowest with cord blood, and patients could thus be more susceptible to infection. But in terms of transplant-related mortality, cord blood is roughly the same when compared with peripheral blood or bone marrow sources.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.